Heather Raymon, Senior Vice President of Research and Development at Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), sold 3,095 shares of common stock on May 19, 2026.
The transactions totaled $27,879, with shares sold at prices ranging from $8.7447 to $9.0104. The weighted average sale price was $9.0078.
The sale comes as the stock declined 18.6% over the past week, though shares remain up 296% over the last year. According to Bond.az analysis, the stock currently appears overvalued relative to its Fair Value estimate.
These sales were executed under a “sell-to-cover” policy to satisfy tax withholding obligations related to restricted stock units. The sales were automatic and not at Ms. Raymon’s discretion.
Following these transactions, Ms. Raymon directly holds 148,228 shares of common stock.
In other recent news, Artiva Biotherapeutics announced promising clinical trial data for its AlloNK therapy combined with rituximab, showing 71% of refractory rheumatoid arthritis patients achieved an ACR50 response. Additionally, Diego Miralles was appointed President and Head of Research and Development.
H.C. Wainwright raised its price target to $35 from $15, maintaining a Buy rating.
